-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, Collie Pharmaceutical-B (01672.HK) announced that its strategic partner Sagimet Biosciences Inc. (Sagimet), a clinical-stage biopharmaceutical company dedicated to developing fatty acid synthase (FASN, a key regulator of lipid synthesis) inhibitors for acne, has completed the first patient administration of ASC40 in the US phase III clinical trial AURORA. The trial was administered to adults with moderate to severe acne, ages 12 and 12. It was carried out among the above young people. AURORA aims to support the submission of potential New Drug Marketing Applications (NDA) in the US. The trial was based on the positive phase III clinical results obtained by Goli and the subsequent 52-week open label extension study data.

Zhitongcaijing·10/23/2026 00:09:11
Listen to the news
Zhitong Financial App News, Collie Pharmaceutical-B (01672.HK) announced that its strategic partner Sagimet Biosciences Inc. (Sagimet), a clinical-stage biopharmaceutical company dedicated to developing fatty acid synthase (FASN, a key regulator of lipid synthesis) inhibitors for acne, has completed the first patient administration of ASC40 in the US phase III clinical trial AURORA. The trial was administered to adults with moderate to severe acne, ages 12 and 12. It was carried out among the above young people. AURORA aims to support the submission of potential New Drug Marketing Applications (NDA) in the US. The trial was based on the positive phase III clinical results obtained by Goli and the subsequent 52-week open label extension study data.